期刊文献+

晚期非小细胞肺癌临床预后因素分析 被引量:1

下载PDF
导出
摘要 目的探讨中国人(华南地区)晚期非小细胞肺癌(NSCLC)(ⅢB/Ⅳ期)的临床预后因素。方法对112例晚期NSCLC患者的临床资料进行单因素和多因素生存回归分析。结果晚期NSCLC患者的中位生存时间是13个月,1 a总生存率55.6%,2 a总生存率17.1%。多因素Cox回归分析PS评分、化疗次数、酪氨酸激酶抑制剂(TKI)的应用和分期是影响晚期NSCLC预后的因素,其中胸水是ⅢB期NSCLC预后的独立因素;化疗次数、肝和脑转移是Ⅳ期NSCLC患者的独立预后因素。结论中国华南人群中,晚期NSCLC(ⅢB/Ⅳ期)患者和预后生存密切相关的临床因素有分期、PS评分、TKI的应用以及化疗次数。
出处 《山东医药》 CAS 北大核心 2010年第17期78-80,共3页 Shandong Medical Journal
  • 相关文献

参考文献8

  • 1Ohe Y,Ohashi Y,Kubota K,et al.Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:four-arm cooperative study in Japan[J].Ann Oncol,2007,18(2):317-23.
  • 2Fossella F,Pereira JR,von Pawel J,et al.Randomized,multinational,phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer:the TAX 326 study group[J].J Clin Oncol,2003,21(16):3016-3024.
  • 3Mandrekar SJ,Schild SE,Hillman SL,et al.A prognostic model for advanced stage nonsmall cell lung cancer.Pooled analysis of North Central Cancer Treatment Group trials[J].Cancer,2006,107(4):781-792.
  • 4Gullón Blanco JA,Suárez Toste I,et al.Chemotherapy and survival in advanced non-small cell lung carcinoma:is pneumologists' skepticism justified[J]? Arch Bronconeumol,2006,42(6):273-277.
  • 5韩宇,徐建明,段海清,宋三泰,刘晓晴,张扬,张京生.EGFR基因突变与吉非替尼治疗晚期非小细胞肺癌的疗效和预后的关系[J].中华肿瘤杂志,2007,29(4):278-283. 被引量:25
  • 6汤良,关玉梅,聂学诚,邢宝华.晚期非小细胞肺癌患者生活质量和化疗周期数相关性探讨[J].肿瘤基础与临床,2008,21(3):255-256. 被引量:6
  • 7高云,方健,刘叙仪,林宝和,安彤同,高非.305例非小细胞肺癌骨转移的诊断、治疗及预后分析[J].中国肺癌杂志,2006,9(4):357-361. 被引量:18
  • 8Perona R,Massuti B,Rosell R.Reflections on the IASLC 12th world conference on lung cancer[J].Clin Transl Oncol,2008,10(2):67-69.

二级参考文献35

  • 1徐建明,宋三泰.表皮生长因子受体酪氨酸激酶靶向药物与化疗联合应用的合理设计[J].中华肿瘤杂志,2004,26(6):321-323. 被引量:20
  • 2王彬,张湘茹,储大同.易瑞沙在晚期非小细胞肺癌化疗失败后的作用[J].中华肿瘤杂志,2004,26(12):742-745. 被引量:53
  • 3吴斌,杨志雄,李文,张卫珍.肺癌骨转移的特点和规律的探讨[J].实用肿瘤学杂志,1997,11(1):32-34. 被引量:16
  • 4董惟誉 杨丽珠 等.核素骨显像诊断骨肿瘤的价值[J].中华核医学杂志,1988,8:87-89.
  • 5Wilson MA, Calhoun FW. The distribution of skeletal metastases in breast and pulmonary cancer: Concise communication. J Nucl Med,1981,22(6) :594-600.
  • 6Donato AT, Ammerman EG, Sullesta O. Bone scanning in the evaluation of patients with lung cancer. Ann Thorac Surg,1979,27(4) : 300-304.
  • 7Jacobson AF, Cronin EB, Stomper PC, et al. Bone scans with one or two new abnormalities in cancer patients with no known metastases : frequency and serial scintigraphic behavior of benign and malignant lesions. Radiology, 1990,175 ( 1 ) : 229-232.
  • 8Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ , double-blind, randomized trial the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol,2003,21(16):3150-3157.
  • 9Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer,2000,88( 12 Suppl) : 3033-3037.
  • 10Merrick MV, Merrick JM. Bone scintigraphy in lung cancer: a reappraisal. Br J Radiol,1986,59(708) : 1185-1194.

共引文献46

同被引文献17

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部